Eyegate Pharmaceuticals (NASDAQ:EYEG) will be releasing its earnings data on Wednesday, February 21st. Analysts expect Eyegate Pharmaceuticals to post earnings of ($0.24) per share for the quarter.
Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at $0.64 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.01. The firm has a market cap of $10.98 and a PE ratio of -0.55. Eyegate Pharmaceuticals has a fifty-two week low of $0.49 and a fifty-two week high of $3.90.
An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. boosted its position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 247,319 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,988 shares during the period. Vanguard Group Inc. owned 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent SEC filing. 12.58% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on EYEG. HC Wainwright reissued a “buy” rating and issued a $3.00 price target (down from $5.00) on shares of Eyegate Pharmaceuticals in a report on Tuesday, February 6th. ValuEngine upgraded Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
ILLEGAL ACTIVITY WARNING: “Eyegate Pharmaceuticals (EYEG) Set to Announce Earnings on Wednesday” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/02/20/eyegate-pharmaceuticals-eyeg-set-to-announce-earnings-on-wednesday.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.